Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05112939 · ClinicalTrials.gov registry record · Phase 1
A Study of a Rilpivirine Extended-Release Suspension in Healthy Participants
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 126
- Enrollment target
NCT05112939 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 126 participants.
The verdict
NCT05112939, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 126 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the single dose pharmacokinetics (PK) and evaluate the safety and tolerability of subcutaneous administration of rilpivirine (RPV) long-acting (LA) or RPV LA in combination with cabotegravir (CAB) LA extended release suspensions in different conditions in healthy adult participants.
Interventions
- DRUG CAB LA
- DRUG RPV LA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2021-11-16 |
| Est. Completion | 2024-05-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05112939
The ClinicalTrials.gov registry entry for NCT05112939 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CAB LA is the first listed.
NCT05112939 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05112939 about?
NCT05112939 is a clinical study titled "A Study of a Rilpivirine Extended-Release Suspension in Healthy Participants". The purpose of this study is to characterize the single dose pharmacokinetics (PK) and evaluate the safety and tolerability of subcutaneous administration of rilpivirine (RPV) long-acting (LA) or RPV LA in combination with cabotegravir (CAB) LA extended release suspensions in different conditions in...
What is the current status of trial NCT05112939?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 126 participants. The study started on 2021-11-16. Estimated completion is 2024-05-23.
What interventions are being tested in trial NCT05112939?
The interventions under investigation include: CAB LA (DRUG), RPV LA (DRUG).
Who is sponsoring clinical trial NCT05112939?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.